Twice-a-Year Alzheimer's Drug Trial

✓ Medically reviewed | Published: | Evidence level: 1A
News coverage describes a twice-a-year Alzheimer's treatment that reportedly cut the rate of brain decline roughly in half in a clinical trial. The result is early and has not been fully scrutinised, but it highlights a push toward less burdensome dosing after anti-amyloid antibodies such as lecanemab and donanemab showed modest slowing of decline. Patients and families should treat the findings as promising but preliminary.
📅 Published:
✓ Reviewed by iMedic Medical Editorial Team
📄 Neurology

Quick Facts

US Alzheimer's Cases
About 7 million adults
Reported Trial Signal
Decline roughly halved
Dosing Interval
Twice a year
Approved Antibodies
Lecanemab, donanemab

What does the twice-a-year Alzheimer's drug trial report show?

Quick answer: Media reports say a twice-yearly Alzheimer's drug reduced the pace of brain decline by about half in a trial, but full peer-reviewed details are needed to judge the result.

Coverage from outlets including the New York Post describes a trial of a new Alzheimer's treatment, given only twice a year, in which measures of brain decline progressed at roughly half the usual rate. The word "thrilling" in the headline reflects enthusiasm from commentators, but headline summaries rarely capture critical details: which outcome was measured, in which patient population, over what period, and compared with what control group.

Those details matter. In Alzheimer's research, "brain decline" can refer to imaging measures such as brain shrinkage, to biomarkers such as amyloid or tau levels, or to clinical scales of memory and daily function. A halving of a biomarker change does not automatically mean a halving of symptoms. Until the full data are presented at a scientific meeting or published in a peer-reviewed journal, the finding should be considered promising but preliminary, and it is not a treatment currently available to patients outside a trial.

How does this compare with current Alzheimer's antibody treatments?

Quick answer: Lecanemab and donanemab modestly slow decline in early Alzheimer's disease but require frequent dosing and monitoring, which is why less frequent regimens attract interest.

The US FDA granted full approval to lecanemab (Leqembi) in 2023 and approved donanemab (Kisunla) in 2024 for early symptomatic Alzheimer's disease. In the Clarity AD trial, published in the New England Journal of Medicine in 2023, lecanemab slowed decline on the CDR-SB scale by about 27 percent over 18 months compared with placebo. Donanemab's TRAILBLAZER-ALZ 2 trial, published in JAMA in 2023, also showed slowing of decline, particularly in people with lower to intermediate tau burden. Both drugs clear amyloid plaques from the brain, but the clinical benefit is modest and the treatments carry a risk of amyloid-related imaging abnormalities (ARIA), including brain swelling and microbleeds, which can occasionally be serious.

Current regimens involve regular infusions or injections and repeated MRI monitoring. A treatment given just twice a year would reduce clinic visits, infusion-centre capacity demands, and caregiver burden, potentially widening access. Whether a long-interval drug can match or exceed the benefit of existing antibodies, and whether it has a comparable or better safety profile, will depend on the full trial results and on longer follow-up in broader, more diverse patient groups.

What should patients and families do while waiting for more data?

Quick answer: Talk with a neurologist about current approved options, eligibility testing, and clinical trials, and continue proven brain-health measures.

Alzheimer's disease affects roughly 7 million Americans, according to the Alzheimer's Association, and the number is expected to rise with population ageing. Anyone concerned about memory changes should seek a formal evaluation, which may include cognitive testing, MRI, and biomarker confirmation through PET imaging or cerebrospinal fluid or blood-based tests. Only people with confirmed early-stage disease are typically candidates for current anti-amyloid antibodies.

Families interested in emerging therapies can ask a specialist about clinical trial enrolment through resources such as ClinicalTrials.gov. In the meantime, managing blood pressure, staying physically and socially active, treating hearing loss, and controlling diabetes are evidence-supported ways to support brain health, as emphasised in the Lancet Commission on dementia prevention.

Frequently Asked Questions

No. Based on the reports, it is an investigational treatment studied in a clinical trial. It would need further trials and regulatory review by agencies such as the FDA before it could be prescribed.

No. Slowing decline is not the same as stopping or reversing Alzheimer's disease. Even a large relative slowing means progression continues, only more gradually.

The best-known risk is ARIA, which involves brain swelling or small bleeds seen on MRI. It is often without symptoms but can occasionally be serious, which is why MRI monitoring is part of current treatment.

References

  1. van Dyck CH, et al. Lecanemab in Early Alzheimer's Disease. New England Journal of Medicine. 2023.
  2. Sims JR, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023.
  3. Alzheimer's Association. Alzheimer's Disease Facts and Figures.
  4. New York Post. Alzheimer's brain decline slashed in half by 'thrilling' new twice-a-year drug: trial. November 2026.